$NPCE News

NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting

HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance

NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript

NeuroPace Raises FY2026 Sales Guidance from $98.000M-$100.000M to $99.000M-$101.000M vs $98.910M Est

NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate

NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook

NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript

Neuropace shares are trading higher after the company reported better-than-expected Q4 financial results.

Neuropace shares are trading higher after the company reported better-than-expected Q4 financial results.

NeuroPace Sees Q1 Sales $21.000M-$22.000M vs $21.925M Est

NeuroPace Sees FY2026 Sales $98.000M-$100.000M vs $98.943M Est

Earnings Summary: NeuroPace Q4

NeuroPace Q4 EPS $(0.08) Beats $(0.17) Estimate, Sales $26.588M Beat $24.791M Estimate

Earnings Outlook For NeuroPace

Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock

HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $19

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow